Search Results (3,339)

Banana is a typical climacteric fruit that rapidly undergoes ripening, peel browning, softening, moisture loss, and fungal decay during postharvest storage, leading to severe quality deterioration and a shortened shelf life. In this study, a sodium alginate (SA)-based edible coating enriched with Isodon serra extract (IE) and Plinia cauliflora (jaboticaba) leaf extract (JE) was developed and evaluated for its antioxidant, antifungal, and preservation effects on banana fruit. The two extracts exhibited distinct functional properties: IE showed strong inhibitory activity against Colletotrichum musae, whereas JE displayed superior radical scavenging capacity. When incorporated into the coating system, this functional complementarity translated into improved preservation performance. The composite coating (SA-IE-JE) effectively suppressed anthracnose development, reduced peel browning, and delayed ripening progression, as evidenced by an 11.8% reduction in fruit weight loss (11.48% vs. 13.01%), an 11.6% decrease in MDA accumulation (89.96 vs. 101.75), a 51.3% reduction in PPO activity (526 U/g vs. 1080 U/g), sustained TPC, and a slower increase in total soluble solids after 5 days of storage. All coating treatments improved postharvest quality compared with the uncoated control, while SA-IE and SA-IE-JE generally showed stronger preservation effects than SA alone. In particular, SA-IE-JE was more effective in reducing peel browning, delaying the increase in PPO activity, and suppressing anthracnose lesion expansion. These findings highlight that SA coating supplemented with IE and JE can serve as a promising, environmentally friendly strategy for maintaining banana quality and reducing postharvest disease. Our study provides a potential basis for the development of plant-extract-enriched edible coatings for banana preservation. Full article

Background/Objectives: Nutritional support may improve the tolerance and effectiveness of definitive treatment in patients with head and neck cancer (HNC). The aim of this study was to investigate the potential clinical deterioration in patients who refuse nutritional consultations and oral nutritional supplementation during chemoradiotherapy (CHRT) for HNC. Methods: The study included 52 patients undergoing CHRT for HNC. Among these patients, 22 (42.3%) received nutritional counseling with oral nutritional supplementation (NCONS), while 30 (57.7%) patients refused NCONS (R-NCONS). The study aimed to investigate and compare the association of NCONS with weight loss, blood parameters, CHRT complications, and overall survival (OS) between the two groups. Results: At the end of CHRT, the R-NCONS group exhibited significantly higher CRP levels (18 mg/L vs. 4 mg/L; p = 0.013) and lower prealbumin levels (0.19 g/L vs. 0.27 g/L; p = 0.003) compared with NCONS group. Furthermore, R-NCONS patients experienced a higher rate of overall complications during CHRT (67% vs. 32%; p = 0.013), required enteral nutrition more frequently (20% vs. 0%; p = 0.033), and exhibited greater weight loss (−11% vs. −5%; p < 0.001). However, the 5-year OS did not differ significantly between the groups. Conclusions: The study demonstrates that while NCONS minimizes overall complications during CHRT, its refusal results in weight loss, elevated CRP and depleted prealbumin levels, and a more frequent need for enteral nutrition interventions. Full article

To address the challenge of balancing flame retardancy and dust suppression in conventional coal mine treatment materials, a multi-component synergistic flame-retardant dust-suppressant gel was fabricated using carboxymethyl cellulose (CMC) as the matrix, compounded with ammonium polyphosphate (APP), zinc borate (ZB), and polycarbodiimide (PCDI) as a cross-linking agent. The optimal formulation was determined via orthogonal experimental design combined with performance characterization, yielding a composition of 1 wt% CMC, 8 wt% APP, 2 wt% ZB, and 0.5 wt% PCDI. Systematic evaluations—including wettability tests, thermogravimetric analysis, and fire-extinguishing trials—demonstrated that the resultant CMC-based composite gel exhibits excellent structural stability and environmental tolerance. Specifically, the contact angle on the coal surface decreased sharply from 72.8° to 17.2°, and the mass loss rate after 30 min of wind erosion was merely 4.16%. Treatment with the gel elevated the critical temperature of the coal–oxygen reaction from 70 °C to 80 °C and reduced CO emissions by 40% at 170 °C. Furthermore, the temperatures corresponding to the maximum weight loss rate, ignition, and burnout increased by 12.9 °C, 16.8 °C, and 28.9 °C, respectively. Fire suppression tests revealed that the gel rapidly cools high-temperature coal seams and effectively prevents reignition. Mechanistic investigations indicate that the CMC-PCDI cross-linked network synergizes with the APP-ZB phosphorus–boron flame-retardant system: the three-dimensional gel architecture provides physical encapsulation and water retention, while the intumescent char layer formed by APP-ZB offers efficient oxygen barrier protection. This study provides a reliable gel-based technical solution for the integrated prevention and control of coal dust pollution and spontaneous combustion disasters in underground mines. Full article

Ionizing radiation (IR) damage, whether intentional, accidental, or therapeutic, reverberates throughout the body. The FDA has approved the use of palliative care and leukocyte growth factors for hematologic depletion (H-ARS), but no treatments have been approved for gastrointestinal damage (GI-ARS). Synthetic PIF (sPIF) safely replicates endogenous PIF’s preventative, reparatory, and regenerative effects. Specifically relevant for radiation-induced damage, sPIF reduces oxidative stress. Subcutaneous (SC) sPIF prevents LD100/30 mortality at 2 w post-treatment and restores GI function post-6Gy exposure (in mice). Daily SC sPIF for 14 d, starting 24 h post-LD85/40 (7.17 Gy) total-body ɣ-irradiation (TBI), increases survival 2.76-fold (14.7% (5/34) to 40.7% (24/59); p = 0.0036) by 4 w post-therapy. All sPIF-treated mice survived for the first 10 d, while only 80% survived in the sham group (p = 0.0034). The sPIF-treated group reached 50% survival at 23 di, while this figure was reached at 19 d in the sham-treated group, with a 21% delay. Importantly, sPIF delays weight loss for up to 25 d, increasing weight by ~12% above baseline and improving colon architecture; in the sham, both weight and colon recovery failed. sPIF partially prevents declines in hemoglobin and platelets, with no bleeding/sepsis observed, while WBC counts declined. sPIF’s safety and lack of deleterious drug-to-drug interaction were documented in a First-in-Human, FDA-approved clinical trial for autoimmune disease. Chronic FDA-guided toxicology/toxicokinetic studies demonstrated NOAEL and the highest safety margin. Collectively, sPIF safely and significantly increases survival, weight gain, and colon crypt scale, directly supporting its suitability for FDA-ARS animal-rule approval. Full article

Botrytis cinerea is a major fungal pathogen of grapevine responsible for gray mold, causing significant economic losses worldwide. Under specific environmental conditions, controlled development of Botrytis cinerea may lead to “noble rot,” a quality-enhancing attribute of premium wines; however, the same fungus can rapidly develop into destructive gray mold, causing significant grape losses. Consequently, the challenge is not necessarily the complete eradication of the pathogen, but the regulation of its development to prevent uncontrolled disease progression while preserving grape quality. The present study investigated the potential of using essential oils extracted from selected aromatic plants using ultrasound-assisted hydrodistillation (UAHD) as eco-friendly biocontrol agents against Botrytis cinerea. The extraction process was optimized by evaluating the effects of biomass particle size, ultrasonic power, and distillation time on essential oil yield. Antifungal activity was assessed through in vitro poisoned food and disk diffusion assays and validated in vivo on artificially inoculated grape berries by evaluating disease incidence, disease severity, treatment efficacy, and weight loss. Ultrasound pretreatment increased essential oil yield by up to 29.58% compared with conventional hydrodistillation, with optimal conditions achieved using 1 cm biomass, 150 W ultrasonic power, and 85 min distillation. Oregano, thyme, sage, and lemon balm essential oils achieved 100% inhibition of Botrytis cinerea mycelial growth at the tested concentrations, whereas lavender essential oil showed 95.03% inhibition at 0.125% and complete inhibition at 0.25%. In vivo, essential oil formulations markedly reduced gray mold development, with the 2.0% formulation providing the highest treatment efficacy and the lowest disease severity. These findings show that UAHD-derived essential oils represent promising sustainable alternatives for the management of Botrytis cinerea in viticulture. However, these findings represent preliminary evidence obtained under controlled in vitro conditions, necessitating further validation in real-world applications. Full article

Glucagon-like peptide-1 (GLP-1) receptor agonists and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists have transformed obesity management by producing substantial, sustained weight loss and improving metabolic health. Alongside these benefits, their effects on appetite, food intake, and gastrointestinal function have raised increasing interest in the nutritional consequences of pharmacologically induced weight loss. Although reductions in energy intake contribute to therapeutic efficacy, they may also influence protein intake, dietary quality, micronutrient adequacy, and skeletal muscle health, particularly in individuals with pre-existing nutritional vulnerability. This narrative review summarizes current evidence regarding nutritional considerations during GLP-1-based therapy, including changes in dietary intake, protein and micronutrient adequacy, body composition, muscle health, and nutritional assessment. Particular attention is given to populations at increased nutritional risk, practical approaches to nutritional monitoring, and strategies to support adequate nutrition during treatment. Current evidence suggests that nutritional responses to GLP-1-based therapy are heterogeneous and cannot be adequately evaluated using body weight alone. Assessment of dietary intake, body composition, muscle function, physical performance, and individual clinical characteristics provides a more comprehensive understanding of nutritional status than anthropometric measures alone. While routine supplementation or intensive monitoring is not supported for all patients, a risk-based and individualized approach appears appropriate, particularly for older adults and individuals with sarcopenic obesity, previous bariatric surgery, chronic gastrointestinal disease, or persistent treatment-related gastrointestinal symptoms. Future research should establish clinically meaningful nutritional outcomes and determine which nutritional interventions improve patient-centered outcomes during long-term obesity management. Full article

Background/Objectives: Obesity is a chronic, progressive, and relapsing disease that requires long-term, multidisciplinary management rather than episodic weight-loss treatment. Although novel incretin-based anti-obesity pharmacotherapies, including GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists, have markedly improved the clinical management of obesity, weight reduction alone does not fully capture treatment success. Body composition, lean mass preservation, physical function, nutritional adequacy, psychological well-being, adherence, and long-term weight-loss maintenance are increasingly recognized as essential therapeutic outcomes. This narrative review critically examines the role of lifestyle medicine as a co-therapeutic strategy during modern anti-obesity pharmacotherapy, with particular attention to physical activity, nutrition, behavioral support, and individualized monitoring. Methods: A narrative literature search was conducted in PubMed up to June 2026. The review included studies addressing adults with overweight or obesity and evidence related to anti-obesity pharmacotherapy, physical activity, nutrition, body composition, functional outcomes, eating behavior, quality of life, treatment tolerability, adherence, weight regain, and long-term maintenance. Results: Current evidence indicates that incretin-based therapies produce substantial and clinically meaningful weight loss, but pharmacological efficacy may be limited by reductions in lean mass, gastrointestinal adverse events, inadequate nutritional intake, treatment discontinuation, and weight regain after drug withdrawal. Physical activity should be considered a therapeutic component rather than only a tool for increasing energy expenditure, as aerobic exercise supports cardiometabolic health and cardiorespiratory fitness, while resistance training helps preserve muscle strength, bone health, and functional capacity. Nutritional strategies are equally important, particularly during appetite suppression, to maintain adequate protein, fiber, fluids, micronutrients, and diet quality. Behavioral factors, including sleep, stress, mood, stigma, self-regulation, and the food environment, may influence adherence and long-term outcomes. Conclusions: Novel anti-obesity drugs should not be viewed as replacements for lifestyle medicine but as powerful tools within an integrated chronic-care model. The goal of treatment should move beyond maximal body-weight reduction to durable improvements in body composition, metabolic health, physical function, nutritional status, quality of life, and weight-loss maintenance. Full article

Glucagon-like peptide (GLP)-1 receptor agonists (GLP-1RAs) (including medications that contain GLP-1 and other RAs), hereafter referred to as GLP-1 medicines, have significantly advanced the management of metabolic disease and weight management. Obesity is highly prevalent among cancer survivors at the time of diagnosis, and cancer treatments are associated with subsequent changes in weight, either gain or loss. Research has shown that obesity can adversely affect cancer treatment outcomes and survivorship, leading researchers to investigate the potential integration of GLP-1 medicines into oncology care. There is growing interest in understanding the effects of GLP-1 medicines on weight loss and cancer-related outcomes among individuals with obesity who are taking anticancer therapies, as well as individuals treated for cancer in the past who are long-term survivors. This review examines the literature to characterize what is known about GLP-1 medicine use among cancer survivors. The current literature, though limited and largely retrospective, suggests that GLP-1 medicines may contribute to weight loss among cancer survivors, with outcomes varying by cancer stage and type of anticancer therapy. It is important for healthcare providers to consider the potential negative impact of these GLP-1 medications on their patients, especially those with cancer cachexia or sarcopenic obesity, as well as those undergoing anticancer treatments that often lead to weight loss. While there is preclinical evidence suggesting that there are weight-loss independent effects that may be beneficial to individuals with cancer, use of GLP-1 medicines in patients of normal weight for reasons other than treatment of type 2 diabetes should be initiated with caution. On the positive side, these agents may help mitigate therapy-related toxicities, such as cardiotoxicity, with the potential to enhance survivorship outcomes. Unfortunately, there is a notable lack of well-designed randomized controlled trials evaluating the effects of GLP-1 medicines on weight loss, clinical endpoints, and cancer-related outcomes. Advancing the field requires a focus on elucidating the interactions between GLP-1 medicines and anticancer therapies, particularly their impact on treatment efficacy, nutritional status, and overall patient outcomes, both during treatment and in the long term. Full article

Background/Objectives: Pregnancy is associated with profound hormonal, hemodynamic, and metabolic changes that may affect the auditory and vestibular systems. However, evidence regarding pregnancy-related audiological disturbances remains limited due to the low incidence of these conditions and the scarcity of dedicated studies. The study aimed to identify the most commonly reported audiological changes occurring during pregnancy and the postpartum period with an emphasis on sudden sensorineural hearing loss (SSNHL), its risk factors, clinical presentation, and treatment methods. Methods: A literature search was conducted in PubMed, Embase, Web of Science, and Google Scholar from database inception to November 2025 using combinations of the keywords “pregnancy”, “hearing loss”, and “audiological changes”. The review is based on twenty-four original articles that met the preselected criteria. Results: Current evidence does not support pregnancy as an independent risk factor for SSNHL; the prevalence in obstetric patients is lower than in the control groups. Most cases occur during the third trimester or the postpartum period. Pre-pregnancy obesity and elevated blood pressure were identified as potential risk factors. Higher income levels and rural residency are associated with an increased incidence of SSNHL, whereas gestational diabetes, pre-eclampsia, and pregnancy-related weight gain showed no consistent association with SSNHL. Audiometric studies demonstrated mild, predominantly low-frequency, hearing threshold elevations that were generally transient and resolved after delivery. Tinnitus, nausea, aural fullness, dizziness, and vertigo were the most common ear-related complaints. Most of these disorders resolve spontaneously, but some studies suggest steroid treatment should be introduced. Intratympanic corticosteroid therapy was the most frequently investigated treatment for SSNHL and was associated with favorable hearing outcomes in most reported cases. Limited evidence suggests that Dextran 40 may improve hearing outcomes when used as an adjunctive therapy. Conclusions: Potentially transient cochleovestibular impairment during pregnancy and the postpartum period should not be underestimated and requires further evaluation. Pregnancy-related physiological adaptations may contribute to transient auditory and vestibular disturbances, particularly during late pregnancy and the postpartum period. Although current evidence does not indicate an increased risk of SSNHL during pregnancy, prompt recognition and management remain important to prevent long-term hearing impairment. Further high-quality studies are required to clarify the underlying mechanisms and establish evidence-based treatment recommendations for pregnant patients with SSNHL. Full article

In 1994, leptin was identified as a hormone that signals the brain to reduce food intake and increase energy expenditure. Leptin was initially considered a breakthrough therapy for obesity. This was largely based on animal studies, showing that leptin reversed obesity in individuals with congenital leptin deficiency and normal leptin receptor sensitivity. However, due to leptin resistance, leptin therapy failed to reduce weight in common human obesity. Consequently, interest in leptin waned for many years. However, recent studies in animal models of common obesity show that combining leptin with other weight-loss-stimulating agents, can restore hypothalamic leptin sensitivity and induce a greater reduction of body weight than after single drug treatment. Moreover, after initially reducing weight by combination therapy, leptin monotherapy proved enough to maintain reduced body weight. The strongest evidence for restoring leptin’s weight-lowering actions in common obesity to date comes from mouse studies in which leptin was combined with other pharmacotherapies. However, it is unclear at this moment whether this strategy also can be used to treat common human obesity successfully. Overcoming leptin resistance, by combining leptin with other pharmacotherapies, is a promising strategy that needs to be further investigated in humans with obesity. Full article

Background/Objectives: Recurrent pregnancy loss (RPL) has traditionally been investigated predominantly through maternal factors, while the clinical role of paternal assessment remains inconsistently defined. Current guidelines differ substantially regarding semen analysis, sperm DNA fragmentation (SDF), genetic testing, and referral for andrological evaluation. This review aimed to compare contemporary guideline recommendations, critically appraise the directness, prognostic value, and clinical utility of the supporting evidence, and classify paternal assessment strategies as routine, selective, or investigational. Methods: A structured narrative review was conducted using PubMed and Scopus searches through June 2026. International RPL, obstetric, reproductive medicine, and andrology guidelines were compared. Evidence from systematic reviews, meta-analyses, clinical studies, and clinically relevant molecular investigations was evaluated according to its directness to RPL populations, diagnostic and prognostic value, and evidence that test-guided interventions improve miscarriage or live-birth outcomes. Results: Routine paternal assessment should include age, reproductive and medical history, body weight, lifestyle, medication exposure, and relevant environmental or occupational risks. Conventional semen analysis is appropriate primarily when RPL coexists with infertility or suspected male reproductive disease. SDF is the most extensively studied advanced paternal biomarker and is frequently elevated in RPL cohorts, but findings vary by assay and comparator population, while prospective prediction of subsequent live birth and benefit from SDF-directed treatment remain unproven. Parental karyotyping has established counselling value but should be risk-stratified. Sperm aneuploidy testing, oxidative stress assays, seminal microbiome profiling, epigenetic biomarkers, and biomarker-directed interventions remain investigational. Conclusions: Paternal assessment in RPL should be couple-based, clinically targeted, and evidence-informed. Current evidence supports routine clinical evaluation, selective use of semen analysis, SDF testing, genetic assessment, and reproductive urology referral, and restriction of unvalidated biomarkers and treatments to research settings. Full article

Background: With the growing popularity of golf, the wood consumption and white pollution caused by traditional wooden and plastic golf tees create an urgent need for green, degradable, high-performance alternatives. Materials and Methods: To address this, a novel approach for the green fabrication of high-performance composites was developed utilizing a single agricultural solid waste (chestnut shells) bridged by an extremely low proportion (4 wt%) of a thermoplastic agent (polylactic acid, PLA). A mild dilute hydrochloric acid hydrothermal pretreatment selectively removed hemicellulose to expose active hydroxyl groups, followed by a wet hot-pressing process optimized at 80 °C, 4 h, 15 MPa, and 180 mesh. Results: Under these conditions, the resulting CS-APLA composite tees exhibited a bending strength of 86.32 ± 6.46 MPa and a dynamic impact toughness of 104.89 ± 5.26 kJ/m², representing significant increases of 64.86% and 41.69%, respectively, compared to the pure biomass material, and outperforming conventional commercial wooden tees. A 75-day soil burial test demonstrated a weight loss of approximately 45.42%, confirming a balanced degradation rate. Conclusions: Multi-scale characterization confirmed that the synergistic reinforcement relies objectively on an acid-treatment-induced hydrogen-bonding network coupled with in situ polymer-bridged microdomains formed by PLA flow filling during hot-pressing. This study provides a sustainable route for the high-value utilization of agricultural solid waste. Full article

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are transforming obesity management, yet landmark trials often incompletely measure and report a central mediator of response: dietary intake. Because GLP-1RAs promote weight loss primarily by suppressing appetite and reducing energy consumption, capturing changes in dietary intake is essential to interpreting efficacy, safety, and translation into clinical care. This perspective argues that failure to measure and report comprehensive dietary intake raises concerns under four core bioethical principles. It undermines autonomy by limiting evidence for shared decision-making across the treatment continuum. It challenges non-maleficence because inadequate energy, protein, and micronutrient intake may contribute to lean mass loss and nutrient deficiencies, particularly in vulnerable populations. It weakens beneficence because failing to report a measurable mediator diminishes the scientific value of research requiring substantial investment and participant burden. It raises justice concerns because the equitable distribution of assessment burden and access to resulting nutritional care cannot be evaluated without transparent reporting. To meet the ethical and scientific obligations of clinical research, future trials should preregister dietary intake as a key secondary or safety endpoint. Investigators should report total energy, macronutrient, and micronutrient distribution at baseline and serial follow-up alongside dietary assessment methods, food composition databases, and assessor training. Journal editors, funders, and regulatory bodies should support development of consensus-based, nutrition-specific reporting recommendations aligned with CONSORT principles and encourage preregistration of dietary trial endpoints. Registered dietitian nutritionists should be prospectively integrated into GLP-1RA trial teams from design through data interpretation. Advancing the standard of obesity care requires that the research community look beyond the scale and ground clinical translation in the nutritional context in which pharmacotherapy operates. Full article

Background: Chronic pulmonary aspergillosis (CPA) is a slowly progressive pulmonary fungal disease, predominantly caused by Aspergillus fumigatus, which develops in patients with pre-existing structural lung abnormalities. Chronic cavitary pulmonary aspergillosis (CCPA), the most common form of CPA, is characterized by one or more pulmonary cavities, with or without intracavitary fungal balls (aspergillomas), and requires prolonged oral triazole therapy. Long-term treatment may be limited by adverse events, drug–drug interactions, and the need for therapeutic drug monitoring with conventional azoles. Case Presentation: A 69-year-old former smoker with a history of breast cancer and right upper lobectomy for pulmonary adenocarcinoma presented with fever, productive cough, hyporexia, sarcopenia, and an unintentional 6 kg weight loss over three months. Two years earlier, she had undergone atypical pulmonary resection for an Aspergillus fumigatus aspergilloma and had been treated with amphotericin B followed by voriconazole for six months. HRCT revealed a recurrent intracavitary fungal lesion within a residual post-surgical cavity with extensive inflammatory consolidation. Bronchoalveolar lavage demonstrated a positive galactomannan index (4.74) and septate fungal hyphae on cytology, supporting the diagnosis of recurrent CCPA. Treatment with oral isavuconazole resulted in clinical recovery, weight gain, and complete radiological resolution after six months, without treatment-related adverse events or QTc abnormalities. Conclusions: This case highlights the successful outpatient management of CCPA developing within a persistent post-lobectomy cavity despite previous surgical resection and antifungal therapy. The favourable clinical response, excellent tolerability, and absence of treatment-related toxicity support the growing evidence that isavuconazole may represent a valuable therapeutic option for selected patients with recurrent CCPA. Full article

Cellulose acetate (CA) is a promising bio-derived membrane material for water treatment; however, its limited availability of active functional sites can restrict its affinity toward dissolved pollutants. In this study, a cellulose acetate membrane was fabricated by phase inversion and subsequently functionalized through novel direct graft copolymerization with bio-based itaconic acid (IA) using potassium persulfate (KPS) as an initiator in an aqueous medium. The grafting approach introduced carboxylic functional groups into the CA matrix, providing additional active sites for pollutant removal. The successful grafting was confirmed by UV–Vis and 1H NMR spectroscopy, while XRD indicated changes in the structural organization of the polymer matrix. SEM/EDS characterization further revealed morphological changes associated with grafting, and cross-sectional SEM showed the development of finger-like, continuous pore channels within the modified membrane. The effects of reaction time, IA concentration, and KPS concentration on the grafting percentage were systematically evaluated, with grafting increasing up to an optimum range before declining at excessive monomer or initiator concentrations. Thermal analysis demonstrated improved stability after grafting, with the 6.6% grafted CA-g-IA membrane exhibiting an initial decomposition temperature of 351 °C and a reduced weight loss of 85% at 500 °C, compared with 344 °C and 91%, respectively, for pristine CA. The 6.6% CA-g-IA membrane was subsequently evaluated for the removal of Cu(II) and methylene blue (MB) from aqueous solutions. Cu(II) uptake was strongly influenced by contact time, solution pH, initial concentration, and grafting percentage, with the highest performance observed around pH 6 and 240 min contact time. The membrane also maintained its Cu(II)-binding performance over four regeneration cycles following HNO₃ treatment. Overall, direct IA grafting provides a simple bio-based functionalization strategy for enhancing the pollutant-binding functionality of cellulose acetate membranes, demonstrating potential for the removal of metal ions and cationic dyes from contaminated water. Full article